CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of CTX-112’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for CTX-112 is expected to reach an annual total of $65 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CTX-112 Overview

CTX-112 is under development for the treatment of relapsed and refractory B-cell malignancies including non-Hodgkin lymphoma, chronic lymphocytic leukemia, small lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma and systemic lupus erythematosus (SLE). The therapeutic candidate (CAR-T) comprises of genetically modified allogeneic T cells expressing chimeric antigen receptors targeting cells expressing B lymphocyte antigen CD19. It is administered through intravenous route and is being developed based on CRISPR's gene-editing technology.

CRISPR Therapeutics Overview

CRISPR Therapeutics (CRISPR) is a gene editing company. It focuses on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a gene-editing technology that modifies, deletes, or corrects disease-causing abnormalities at its genetic sources. Its major development programs include ex vivo programs involving gene editing of hematopoietic cells; ex vivo programs in immuno-oncology; in vivo programs targeting the liver and additional in vivo programs targeting other organ systems including muscle and lung. It has research and development operations in Cambridge, Massachusetts, the US and business operations in London, the UK. CRISPR is headquartered in Zug, Switzerland.
The company reported revenues of (US Dollars) US$371.2 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$1.2 million in FY2022. The operating loss of the company was US$222.5 million in FY2023, compared to an operating loss of US$673.2 million in FY2022. The net loss of the company was US$153.6 million in FY2023, compared to a net loss of US$650.2 million in FY2022. The company reported revenues of US$0.5 million for the first quarter ended March 2024, a decrease of 99.7% over the previous quarter.

For a complete picture of CTX-112’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.